Inclusion Criteria:

• Defined region of myocardial dysfunction related to previous myocardial infarction involving the anterior, lateral, posterior or inferior walls, > 12 weeks old at the scheduled time of MyoCell™ implantation procedure
• Patients must have an implantable cardioverter defibrillator (ICD) in place or, patients must receive ICD placement during the CABG procedure or 3 to 4 days after the CABG procedure
• Planned CABG procedure for revascularization
• Heart failure patient in New York Heart Association Symptom Class 2 or 3 who is on optimal medical therapy
• Age > 18 and < 80 years
• Able to undergo surgical biopsy of the skeletal muscle and successful culture of the harvested myoblasts
• Target region wall thickness > 6 mm by echocardiography
• Left ventricular ejection fraction > 20% and < 40% by radionuclide ventriculography or left ventricular angiography at screening
• If a female of childbearing potential, urine pregnancy test must be negative
• Able to give written informed consent

Exclusion Criteria:

• Patient medically unable to undergo CABG surgery
• Any patient who has had a documented myocardial infarction (ECG changes or elevated cardiac enzymes consistent with MI) within 30 days of the scheduled surgical revascularization and cellular implantation procedure.
• Known sensitivity to gentamicin sulfate and/or amphotericin-B
• Exposure to any investigational drug or procedure within 4 weeks prior to study entry
• The use or expected use of antineoplastic drugs
• History of skeletal muscle disease, either primary (i.e., myopathy) or secondary (i.e., ischemic) or any underlying myopathy such as myasthenia gravis, muscular dystrophy, etc.) as determined by a board certified pathologist examining sample of patients muscle biopsy
• Previous angiogenic therapy and/or myocardial laser therapy
• History of cancer within 5 years, except for basal cell carcinoma of the skin
• PSA suggestive of carcinoma of the prostate (i.e., > 4)
• Patient with CEA >2.5 ng/mL or end stage renal disease
• Patients with active infectious disease and/or who are known to have tested positive for HIV, HTLV, HBV-sAg, HCV, CMV and/or syphilis. If the panel includes antibodies to the HBc and HBV-sAg, then an expert will be consulted.
• Females who are pregnant or nursing. Females of childbearing potential must be using to the investigator's satisfaction, a medically accepted method of birth control (e.g., but not limited to, oral or implanted contraceptive therapy or intrauterine devices) and agree to continue for the duration of the study.
• Any illness which might affect patient’s survival over the study follow-up period
• Any illness which, in the Investigator’s judgment, will interfere with the patient’s ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results.
• Patient with an any previous cardiac surgery
• Patient with valvular disease greater than mild in degree which is considered the primary cause of their heart failure
• Patient in New York Heart Association Symptom Class 1 or 4
• Patient with serum creatinine > 2.5
• No informed consent or unable to provide informed consent